Somatostatin Analogs Market Size, Share & Trends Analysis Report By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, Neuroendocrine Tumors), By Region And Segment Forecasts, 2019 - 2026

Published: Oct, 2019 | Pages: 90 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global somatostatin analogs treatment market size is expected to reach USD 8.9 billion by 2026, expanding at a CAGR of 6.3% during the forecast period, according to a new report by Grand View Research, Inc. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.

Presence of strong pipeline products is one of the major factors driving the market growth over the forecast period. For instance, Camurus AB is developing CAM2029 for the treatment of acromegaly and is currently under phase 3 clinical trial. This product comprises of octreotide as its main ingredient. The product is also under phase 1/2 trials for the treatment of neuroendocrine tumors. Furthermore, Dauntless Pharmaceuticals is developing DP1038, an intranasal octreotide, and is currently under clinical development.

Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.

In addition, this network exhibits at the medical trade shows and medical meetings such as NANETs, ASCO, Healing NET Foundation, ASCO GI, The American Association of Endocrine Surgeons, Interventional Radiology, Digestive Disease Week, and local fairs to create awareness pertaining to NETs among population.

In addition, in January 2018, Midatech Pharma PLC received confirmation in oral formulation from Polish regulators for its first in-human analysis of sustained release product Q-Octreotide (MTD201). The product is aimed to be used as an alternative of the commercial leading product, Sandostatin LAR.

Presence of key players such as Novartis AG, Ipsen Pharma, Pfizer Inc., Sun Pharmaceutical Industries Ltd and Chiasma Inc. is expected to fuel to the overall market growth. Involvement of major players in new product development is considered to be the high contributing factor for the SSAs market.

Further key findings from the report suggest:

• Octreotide held the largest market share in 2018 due to its various therapeutic applications

• Pasireotide is estimated to be the fastest growing segment over the forecast period

• Acromegaly held the largest share in 2018 owing to its increase prevalence

• North America dominated the market in 2018 owing to presence of key players such as Pfizer Inc. and Novartis AG

• Asia Pacific is estimated to be the fastest growing segment with a CAGR of 9.0% over the forecast period

 Table of Contents

Chapter 1. Methodology and Scope
                  1.1. Market segmentation & scope
                  1.2. Market definition
                  1.3. Information procurement
                      1.3.1. Purchased database
                      1.3.2. GVR's internal database
                      1.3.3. Secondary sources & third party perspectives
                      1.3.4. Primary research
                  1.4. Information analysis
                      1.4.1. Data analysis models
                  1.5. Market formulation & data visualization
                  1.6. Data validation & publishing
Chapter 2. Executive Summary
                  2.1. Market Outlook
                  2.2. Segment Outlook
                  2.3. Competitive Insights
Chapter 3. Global Somatostatin Analogs Market Variables, Trends & Scope
                  3.1. Somatostatin Analogs Market Lineage outlook
                      3.1.1. Parent market outlook
                      3.1.2. Related/ancillary market outlook
                  3.2. Penetration & Growth Prospect Mapping
                  3.3. Pipeline Analysis
                  3.4. Market Dynamics
                      3.4.1. Market Driver Analysis
                          3.4.1.1. Increasing incidence and prevalence of acromegaly, NETs
                          3.4.1.2. Presence of pipeline products
                          3.4.1.3. Increasing investments in R&D activities
                      3.4.2. Market Restraint Analysis
                          3.4.2.1. High cost of treatment
                      3.4.3. Industry Analysis - Porter's
                          3.4.3.1. Supplier Power
                          3.4.3.2. Buyer Power
                          3.4.3.3. Substitution Threat
                          3.4.3.4. Threat from new entrant
                          3.4.3.5. Competitive rivalry
                  3.5. PESTEL Analysis
                      3.5.1. Political Landscape
                      3.5.2. Environmental Landscape
                      3.5.3. Social Landscape
                      3.5.4. Technology Landscape
                      3.5.5. Legal Landscape
                  3.6. Major Deals & Strategic Alliances Analysis
                      3.6.1. Joint Ventures
                      3.6.2. Mergers & Acquisitions
                      3.6.3. Licensing & Partnership
                      3.6.4. Technology Collaborations
                      3.6.5. Strategic Divestments
Chapter 4. Somatostatin Analogs Market - Competitive Analysis
                  4.1. Recent developments & impact analysis, by key market participants
                  4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
                  4.3. Public Companies
                      4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
                      4.3.2. Competitive Dashboard Analysis
                      4.3.3. Market Differentiators
                      4.3.4. Synergy Analysis: Major Deals & Strategic Alliances
                  4.4. Private Companies
                      4.4.1. List of key emerging companies
                      4.4.2. Regional network map
Chapter 5. Somatostatin Analogs Market: Type Estimates & Trend Analysis
                  5.1. Definitions & Scope
                  5.2. Type market share analysis, 2018 & 2026
                  5.3. Type Dashboard
                  5.4. Global Somatostatin Analogs Market, by Type, 2015 to 2026
                  5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
                      5.5.1. Lanreotide
                          5.5.1.1. Lanreotide market, 2015 - 2026 (USD Million)
                      5.5.2. Octreotide
                          5.5.2.1. Octreotide market, 2015 - 2026 (USD Million)
                      5.5.3. Pasireotide
                          5.5.3.1. Pasireotide market, 2015 - 2026 (USD Million)
Chapter 6. Somatostatin Analogs Market: Application Estimates & Trend Analysis
                  6.1. Definitions & Scope
                  6.2. Application market share analysis, 2018 & 2026
                  6.3. Application Dashboard
                  6.4. Global Somatostatin Analogs Market, by Application, 2015 to 2026
                  6.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
                      6.5.1. Acromegaly
                          6.5.1.1. Acromegaly market, 2015 - 2026 (USD Million)
                      6.5.2. Neuroendocrine Tumors (NETs)
                          6.5.2.1. NETs market, 2015 - 2026 (USD Million)
                      6.5.3. Others
                          6.5.3.1. Others market, 2015 - 2026 (USD Million)
Chapter 7. Somatostatin Analogs Market: Regional Estimates & Trend Analysis, by Type, Application
                  7.1. Regional Market Snapshot
                  7.2. Regional Market Share and Leading Players, 2018
                  7.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
                      7.3.1. North America
                      7.3.2. Europe
                      7.3.3. Asia Pacific
                      7.3.4. Latin America
                      7.3.5. Middle East & Africa
                  7.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
                      7.4.1. North America
                          7.4.1.1. North America Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.1.2. U.S.
                              7.4.1.2.1. U.S. Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.1.3. Canada
                              7.4.1.3.1. Canada Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                      7.4.2. Europe
                          7.4.2.1. Europe Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.2.2. UK
                              7.4.2.2.1. UK Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.2.3. Germany
                              7.4.2.3.1. Germany Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.2.4. Spain
                              7.4.2.4.1. Spain Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.2.5. France
                              7.4.2.5.1. France Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.2.6. Italy
                              7.4.2.6.1. Italy Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.2.7. Russia
                              7.4.2.7.1. Russia Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                      7.4.3. Asia Pacific
                          7.4.3.1. Asia Pacific Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.3.2. China
                              7.4.3.2.1. China Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.3.3. Japan
                              7.4.3.3.1. Japan Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.3.4. India
                              7.4.3.4.1. India Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.3.5. South Korea
                              7.4.3.5.1. South Korea Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.3.6. Australia
                              7.4.3.6.1. Australia Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.3.7. Singapore
                              7.4.3.7.1. Singapore Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                      7.4.4. Latin America
                          7.4.4.1. Latin America Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.4.2. Brazil
                              7.4.4.2.1. Brazil Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.4.3. Mexico
                              7.4.4.3.1. Mexico Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.4.4. Argentina
                              7.4.4.4.1. Argentina Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                      7.4.5. Middle East Africa
                          7.4.5.1. MEA Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.5.2. South Africa
                              7.4.5.2.1. South Africa Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.5.3. Saudi Arabia
                              7.4.5.3.1. Saudi Arabia Somatostatin Analogs Market, 2015 - 2026 (USD Million)
                          7.4.5.4. UAE
                              7.4.5.4.1. UAE Somatostatin Analogs Market, 2015 - 2026 (USD Million)
Chapter 8. Company Profiles
                  8.1. Strategic Framework
                      8.1.1. Novartis AG
                          8.1.1.1. Company overview
                          8.1.1.2. Financial framework
                          8.1.1.3. Product benchmarking
                          8.1.1.4. Strategic initiatives
                      8.1.2. Sun Pharmaceutical Industries Ltd
                          8.1.2.1. Company overview
                          8.1.2.2. Financial framework
                          8.1.2.3. Product benchmarking
                          8.1.2.4. Strategic initiatives
                      8.1.3. Midatech Pharma PLC
                          8.1.3.1. Company overview
                          8.1.3.2. Financial framework
                          8.1.3.3. Product benchmarking
                          8.1.3.4. Strategic initiatives
                      8.1.4. Ipsen Pharma
                          8.1.4.1. Company overview
                          8.1.4.2. Financial framework
                          8.1.4.3. Product benchmarking
                          8.1.4.4. Strategic initiatives
                      8.1.5. Chiasma, Inc.
                          8.1.5.1. Company overview
                          8.1.5.2. Financial framework
                          8.1.5.3. Product benchmarking
                          8.1.5.4. Strategic initiatives
                      8.1.6. Peptron, Inc.
                          8.1.6.1. Company overview
                          8.1.6.2. Financial framework
                          8.1.6.3. Product benchmarking
                          8.1.6.4. Strategic initiatives
                      8.1.7. CRINETICS PHARMACEUTICALS
                          8.1.7.1. Company overview
                          8.1.7.2. Financial framework
                          8.1.7.3. Product benchmarking
                          8.1.7.4. Strategic initiatives
                      8.1.8. Dauntless Pharmaceuticals
                          8.1.8.1. Company overview
                          8.1.8.2. Financial framework
                          8.1.8.3. Product benchmarking
                          8.1.8.4. Strategic initiatives
                      8.1.9. Camurus AB
                          8.1.9.1. Company overview
                          8.1.9.2. Financial framework
                          8.1.9.3. Product benchmarking
                          8.1.9.4. Strategic initiatives
                      8.1.10. Teva Pharmaceuticals Inc.
                          8.1.10.1. Company overview
                          8.1.10.2. Financial framework
                          8.1.10.3. Product benchmarking
                          8.1.10.4. Strategic initiatives
                      8.1.11. Pfizer Inc.
                          8.1.11.1. Company overview
                          8.1.11.2. Financial framework
                          8.1.11.3. Product benchmarking
                          8.1.11.4. Strategic initiatives

List of Tables

TABLE 1 List of Abbreviation
TABLE 2 North America Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 3 North America Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 4 U.S. Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 5 U.S. Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 6 Canada Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 7 Canada Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 8 Europe Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 9 Europe Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 10 UK Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 11 UK Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 12 Germany Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 13 Germany Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 14 France Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 15 France Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 16 Italy Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 17 Italy Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 18 Spain Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 19 Spain Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 20 Asia Pacific Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 21 Asia Pacific Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 22 Japan Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 23 Japan Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 24 China Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 25 China Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 26 India Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 27 India Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 28 South Korea Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 29 South Korea Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 30 Australia Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 31 Australia Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 32 Singapore Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 33 Singapore Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 34 Latin America Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 35 Latin America Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 36 Mexico Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 37 Mexico Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 38 Brazil Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 39 Brazil Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 40 Argentina Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 41 Argentina Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 42 MEA Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 43 MEA Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 44 South Africa Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 45 South Africa Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 46 Saudi Arabia Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 47 Saudi Arabia Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)
TABLE 48 UAE Somatostatin Analogs Market, By Type, 2015 - 2026 (USD Million)
TABLE 49 UAE Somatostatin Analogs Market, By Application, 2015 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global somatostatin analogs market- Key market driver analysis
FIG. 7 Global somatostatin analogs market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Global somatostatin analogs market - Porter's analysis
FIG. 10 Global somatostatin analogs market - PESTEL analysis
FIG. 11 Global somatostatin analogs market type outlook key takeaways
FIG. 12 Global somatostatin analogs market: Type movement analysis
FIG. 13 Octreotide market estimates, 2015 - 2026 (USD Million)
FIG. 14 Lanreotide market estimates, 2015 - 2026 (USD Million)
FIG. 15 Pasireotide market estimates, 2015 - 2026 (USD Million)
FIG. 16 Global somatostatin analogs market Application outlook key takeaways
FIG. 17 Global somatostatin analogs market: Application movement analysis
FIG. 18 Acromegaly market estimates, 2015 - 2026 (USD Million)
FIG. 19 NETs market estimates, 2015 - 2026 (USD Million)
FIG. 20 Others market estimates, 2015 - 2026 (USD Million)
FIG. 21 Global somatostatin analogs market: Regional movement analysis
FIG. 22 North America somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 23 U.S. somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 24 Canada somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 25 Europe somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 26 U.K. somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 27 Germany somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 28 France somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 29 Spain somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 30 Italy somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 31 Asia Pacific somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 32 Japan somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 33 China somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 34 India somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 35 South Korea somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 36 Australia somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 37 Singapore somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 38 Latin America somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 39 Brazil somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 40 Mexico somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 41 Argentina somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 42 MEA somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 43 South Africa somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 44 Saudi Arabia somatostatin analogs market, 2015 - 2026 (USD Million)
FIG. 45 UAE market, 2015 - 2026 (USD Million)
FIG. 46 Strategy framework